Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]
Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
1.
Does diabetes impact the prognosis of people with colorectal cancer?
2.
The September 2018 issue of Medical Bulletin.
3.
High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment
4.
Medicaid expansion tied to smaller declines in early-stage cancer detection
5.
Researchers study effects of cannabis on sedation, cancer treatment symptoms
1.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Unveiling the Mystery of Castleman's Disease: A Journey to Better Health
4.
MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps
5.
Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
5.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation